Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 803.81M P/E - EPS this Y -50.90% Ern Qtrly Grth -
Income -297.11M Forward P/E -2.69 EPS next Y 24.10% 50D Avg Chg 8.00%
Sales 9.92M PEG - EPS past 5Y - 200D Avg Chg 34.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -9.00%
Recommedations 1.70 Quick Ratio 6.11 Shares Outstanding 68.29M 52W Low Chg 144.00%
Insider Own 8.83% ROA -54.07% Shares Float 48.58M Beta 0.71
Inst Own 96.50% ROE - Shares Shorted/Prior 15.52M/14.25M Price 14.25
Gross Margin 80.15% Profit Margin - Avg. Volume 350,793 Target Price 22.57
Oper. Margin -1,055.43% Earnings Date Nov 7 Volume 908,264 Change -5.63%
About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Phathom Pharmaceuticals, Inc. News
11/19/24 Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know
11/08/24 Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
11/07/24 Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
11/07/24 Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/04/24 Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
11/01/24 Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96%
10/28/24 Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
10/27/24 Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
08/19/24 Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
08/08/24 Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
08/08/24 Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
07/30/24 Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
07/29/24 Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
07/18/24 Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
06/09/24 Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now
06/07/24 Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze
05/15/24 Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
05/13/24 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript
05/10/24 The 3 Best Healthcare Stocks to Buy in May 2024
05/09/24 Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
PHAT Chatroom

User Image ShortSqueezeRILY Posted - 10 hours ago

$PHAT lesson learned. Dont buy highly shorted stocks that have zero meme potential. There's just not enough interest in this, other than the short pigs who have clearly demonstrated theyre the ones running the show here.

User Image Mo05e Posted - 10 hours ago

$PHAT looks like a grind to reach $10. Turning bearish to any upside beyond that without news

User Image MontgomeryEL Posted - 17 hours ago

$PHAT no volume nonsense

User Image Walleyeslayer Posted - 17 hours ago

$PHAT 👀

User Image ScottyDoesntKnowMeSon Posted - 18 hours ago

$PHAT some random High Volume sells

User Image Jacobi Posted - 21 hours ago

$BCAX $PHAT what’s up with the numerous accounts spamming MYNZ on this ticker.

User Image IFeelLucky812 Posted - 22 hours ago

$PHAT market potential is 22M patients, if we only get 2% of that group, we are looking at roughly 3.7B in annual revenue with an avg script value of $700. I think these are pretty conservative projections. If we sell at 3-5x revenue we are looking at 11-18B buyout. With no further dilution and none is expected as per their guidance, we could be looking at well over $100/share buyout with debt included. Any other longs with thoughts please chime in. I’m sure most of us will be happy with 1/2 of what I just laid out.

User Image KoleSalinas Posted - 22 hours ago

$BCAX $PHAT LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image Joe_90_ Posted - 1 day ago

$PHAT Zacks upgraded to buy, I'm anticipating the usual "steps up" on relatively low volume 😉

User Image Lolichocho Posted - 1 day ago

$PHAT listened to Stifel call today...not concerned about patent issues at all. This fell from $19 on nothing. Added hard this week, will let this ride right back before taking any off.

User Image GSTX7 Posted - 1 day ago

$PHAT Beautiful chart today. Bottom is in. If I'm shorting this, I'm already out. This thing is about to reverse hard.

User Image steven1x Posted - 1 day ago

$PHAT if missed https://wsw.com/webcast/stifel96/register.aspx?conf=stifel96&page=phat&url=https://wsw.com/webcast/stifel96/phat/2097246

User Image RonIsWrong Posted - 1 day ago

$PHAT q3 increases are very impressive, obviously. But that was before the recent big drop, so Q4 will be a lot more telling given the current ... situation.

User Image ScottyDoesntKnowMeSon Posted - 1 day ago

$PHAT get a nice close over $9.10 and short term party to $10 happens. Then $11. Then I think we build support on the $10-12 range for a bit.

User Image Milanfinest Posted - 1 day ago

$PHAT ok - what i lost here? has been on my watch list and tought that i lost the train- i see a huge gap down and a possible bottom from the graphic- if any hardcore trader (only) can enlight me i ll be glad to share other info on other stocks! ciao <3

User Image kriscory69 Posted - 2 days ago

$PHAT imo after shake out and tutes loading we'll be back on track to $20 in time or a b.o. I'll sit and wait

User Image Ecryder Posted - 2 days ago

$PHAT green is good

User Image dwayne09 Posted - 2 days ago

$PHAT RFK and Donal are like the dark clouds hanging over the entire drug sector, biotech is suffering big time

User Image Joe_90_ Posted - 2 days ago

$PHAT to any Phathom employees reading this thread, thank you for your ingenuity, perseverance, and resilience. We appreciate the efforts made to improve the quality of life for millions of people.

User Image Joe_90_ Posted - 2 days ago

$PHAT possible market up to 22 million patients. This is a medicine for the greater good.

User Image Witherman85 Posted - 2 days ago

$PHAT worst case scenario is later 2030…this entire sell off is a joke. Well done for the short attack here. Doom story for 18 months? This should shoot back as numbers go up

User Image Walleyeslayer Posted - 2 days ago

$PHAT Worst case scenario 2030 and then they have more developments they are working on which will add another patent and additional time.

User Image todd18 Posted - 2 days ago

$PHAT very bullish call. Even if they get a generic challenge they’re going through 2030 with appeals. Other parents are also being filed. Given the new class, FDA needed to look at but confidence was reinforced. Buying opportunity.

User Image Joe_90_ Posted - 2 days ago

$PHAT IP until 2030 regardless. Working on new patents. This is a non issue.

User Image Walleyeslayer Posted - 2 days ago

$PHAT Stated they are on the right side of the law and the legal teams in Washington have indicated that the request should be granted.

User Image GXD_Texas Posted - 2 days ago

@ $PHAT Stifel 2024 Healthcare Conference https://wsw.com/webcast/stifel96/register.aspx?conf=stifel96&page=phat&url=https://wsw.com/webcast/stifel96/phat/2097246

User Image ScottyDoesntKnowMeSon Posted - 2 days ago

$PHAT little volume pushes this back to 10-11

User Image GXD_Texas Posted - 2 days ago

$PHAT small retail cover before conference?

User Image Special_Elvis Posted - 2 days ago

$PHAT Stifel Conference at 1:15 ET today. Hopefully they address this in more detail.

User Image Optimusprimep007 Posted - 2 days ago

$PHAT this got up to 18 or so what happened here to loose 50 percent ?

Analyst Ratings
Needham Buy Sep 13, 24
Needham Buy Sep 6, 24
Needham Buy Aug 30, 24
Needham Buy Aug 23, 24
Needham Buy Aug 19, 24
HC Wainwright & Co. Buy Aug 12, 24
Needham Buy Aug 12, 24
Goldman Sachs Neutral Aug 9, 24
Needham Buy Jul 26, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
TAKEDA PHARMACEUTICAL CO LTD 10% Owner 10% Owner Jan 24 Sell 8.10 3,703,703 29,999,994 3,755,583 01/25/24
Henderson Molly CFO and CBO CFO and CBO Jan 18 Sell 7.7533 6,307 48,900 98,698 01/22/24
Parikh Asit Director Director Nov 06 Buy 7.87 7,500 59,025 55,000 11/08/23
Henderson Molly CFO and CBO CFO and CBO Jun 02 Sell 11.4121 1,960 22,368 68,506 06/05/23
Henderson Molly CFO and CBO CFO and CBO May 22 Sell 12.8744 2,110 27,165 70,466 05/23/23
Curran Terrie President and Chief.. President and Chief Executive Mar 01 Sell 8.5411 1,436 12,265 175,371 03/03/23
Curran Terrie President and Chief.. President and Chief Executive Jan 19 Sell 8.2 5,821 47,732 176,807 01/20/23
Nabulsi Azmi Chief Operating Offi.. Chief Operating Officer May 16 Buy 8.1644 20,000 163,288 785,700 05/16/22
Curran Terrie President and Chief.. President and Chief Executive May 13 Buy 7.4066 20,500 151,835 64,595 05/16/22
Parikh Asit Director Director May 12 Buy 8.00 12,500 100,000 12,500 05/16/22
TAKEDA PHARMACEUTICAL CO LTD 10% Owner 10% Owner Mar 14 Sell 19 18 342 7,459,286 03/16/22
COLA MICHAEL F Director Director Oct 29 Buy 19.00 9,798 186,162 9,798 02/18/22
TAKEDA PHARMACEUTICAL CO LTD 10% Owner 10% Owner Nov 04 Sell 19.93 1,000,001 19,930,020 100,000 11/08/21
Socks David A Director Director Oct 07 Sell 32.36 18,000 582,480 1,211,346 10/08/21
Socks David A Director Director Aug 18 Sell 30.98 18,000 557,640 1,247,346 08/18/21
Socks David A Director Director Jun 29 Sell 34.39 40,000 1,375,600 1,260,945 06/29/21
TAKEDA PHARMACEUTICAL CO LTD 10% Owner 10% Owner Jun 29 Sell 35.54 24,501 870,766 882,240 06/29/21
TAKEDA PHARMACEUTICAL CO LTD 10% Owner 10% Owner Jun 25 Sell 35.07 11,048 387,453 906,741 06/25/21
TAKEDA PHARMACEUTICAL CO LTD 10% Owner 10% Owner Jun 23 Sell 35.16 9,394 330,293 917,789 06/23/21
TAKEDA PHARMACEUTICAL CO LTD 10% Owner 10% Owner Jun 11 Sell 35.21 3,293 115,947 938,712 06/11/21
TAKEDA PHARMACEUTICAL CO LTD 10% Owner 10% Owner Jun 09 Sell 35.03 2,364 82,811 942,005 06/09/21
TAKEDA PHARMACEUTICAL CO LTD 10% Owner 10% Owner Jun 02 Sell 36.21 20,116 728,400 948,669 06/02/21
TAKEDA PHARMACEUTICAL CO LTD 10% Owner 10% Owner May 28 Sell 36.98 20,811 769,591 968,785 05/28/21
TAKEDA PHARMACEUTICAL CO LTD 10% Owner 10% Owner May 26 Sell 36.11 21,541 777,846 989,596 05/26/21
TAKEDA PHARMACEUTICAL CO LTD 10% Owner 10% Owner May 24 Sell 35.42 18,746 663,983 1,011,137 05/24/21
Socks David A Director Director May 21 Sell 33.68 40,000 1,347,200 1,300,945 05/21/21
TAKEDA PHARMACEUTICAL CO LTD 10% Owner 10% Owner May 14 Sell 35.59 11,876 422,667 1,029,983 05/14/21
TAKEDA PHARMACEUTICAL CO LTD 10% Owner 10% Owner May 07 Sell 35.08 7,138 250,401 1,042,870 05/07/21
Nabulsi Azmi Chief Operating Offi.. Chief Operating Officer Apr 05 Sell 36.91 14,500 535,195 780,200 04/05/21
Curran Terrie President and Chief.. President and Chief Executive Mar 23 Option 6.95 11,513 80,015 11,513 03/23/21
Curran Terrie President and Chief.. President and Chief Executive Mar 23 Sell 43.66 11,513 502,658 03/23/21
Socks David A Director Director Jan 13 Sell 35.62 40,000 1,424,800 1,532,945 01/13/21
Nabulsi Azmi Chief Operating Offi.. Chief Operating Officer Jan 05 Sell 33.82 14,500 490,390 823,700 01/05/21
Socks David A Director Director Dec 18 Sell 44.95 79,658 3,580,627 1,572,945 12/18/20
Socks David A Director Director Nov 12 Sell 41.45 30,342 1,257,676 1,652,603 11/12/20
Nabulsi Azmi Chief Operating Offi.. Chief Operating Officer Nov 03 Sell 36.83 14,500 534,035 852,700 11/03/20